1. Home
  2. PTLO vs PLYX Comparison

PTLO vs PLYX Comparison

Compare PTLO & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Portillo's Inc.

PTLO

Portillo's Inc.

HOLD

Current Price

$4.18

Market Cap

323.5M

ML Signal

HOLD

PLYX

Polaryx Therapeutics Inc. Common Stock

N/A

Current Price

$2.25

Market Cap

271.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PTLO
PLYX
Founded
1963
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
323.5M
271.8M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
PTLO
PLYX
Price
$4.18
$2.25
Analyst Decision
Hold
Strong Buy
Analyst Count
11
1
Target Price
$8.06
$10.00
AVG Volume (30 Days)
1.5M
297.0K
Earning Date
05-05-2026
05-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$732,066,000.00
N/A
Revenue This Year
$9.02
N/A
Revenue Next Year
$5.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.03
N/A
52 Week Low
$3.78
$2.01
52 Week High
$11.82
$9.18

Technical Indicators

Market Signals
Indicator
PTLO
PLYX
Relative Strength Index (RSI) 47.51 37.92
Support Level $3.79 $2.04
Resistance Level $4.40 $3.41
Average True Range (ATR) 0.22 0.27
MACD 0.08 0.06
Stochastic Oscillator 60.25 23.31

Price Performance

Historical Comparison
PTLO
PLYX

About PTLO Portillo's Inc.

Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. The company owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, sides and soup, and others.

About PLYX Polaryx Therapeutics Inc. Common Stock

Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.

Share on Social Networks: